Petition for Inter Partes Review by C.R. Bard, Inc.

On February 9, 2016, the USPTO’s Patent Trial and Appeal Board (“Board”) issued a final written decision in an inter partes review regarding a petition filed by C.R. Bard, Inc. (“Petitioner”) over the patentability of claims 1, 2, 5-13, 15-19, 21, and 22 recited in U.S. Patent No. 8,257,325 (“the ‘325 Patent”).  The ‘325 Patent, which issued on September 4, 2012, is owned by Medical Components, Inc., and is drawn to a venous access port with molded and/or radiopaque indicia.  In the decision, the Board denied the institution of the inter partes review because the Petitioner had not established a reasonable likelihood of prevailing that any of the challenged claims, e.g., claims 1, 2, 5-13, 15-19, 21, and 22, of the ‘325 Patent are unpatentable under 35 U.S.C. § 103.  The inter partes review remains pending at the Board and is captioned IPR2015-01660.

By:  Jacqueline A. DiRamio

View Attachment (PDF)